The healthcare industry is in the midst of a substantial shift away from traditional fee-for-service payments, which have historically been associated with excessive and unnecessary care, in favor of value-based options. In January, the Centers for Medicare and Medicaid Services reaffirmed this fact when it announced a goal of having 50 percent of all Medicare payments in alternative payment models by the end of 2018. MIT Holding, Inc. (OTCQB: MITD), a leading provider of post-acute care nationwide, is in a strong position to capitalize on this evolving mindset by providing ambulatory care, in-home intravenous therapies, medical equipment and other recovery needs to help patients avoid unnecessary doctor and hospital visits.

According to a report by Fox Business, the total reduction in overall healthcare spending as a result of ambulatory surgery and therapy options amounts to approximately $2.6 billion annually, and an additional $2.4 billion in savings could be realized if just 50 percent of eligible cases were moved to these non-hospital settings. For MITD, these potential savings could translate into improved financial returns in the coming months. Demand for the company’s low cost, high quality home care is expected to rise as payers realize up to 90 percent savings on infusion services performed in the home instead of the hospital.

The potential market for MITD’s home infusion services is vast. According to Harris Williams & Co., the United States home infusion market is currently valued at $15.9 billion, and continued growth is expected to push the market to $26.7 billion by 2020. In the first quarter of 2015, the company made significant strides toward maximizing its share of this pivotal sector by recording just under $490,000 in consolidated revenues, which was a year-over-year increase of over 133 percent. Leveraging an increase in referrals and the strategic use of subcontractors, MITD also realized a gross profit of nearly $278,000 for the period.

“Our target audience is focused on those needing infusion for recovery,” Tommy Duncan, president of MITD, stated in a news release. “Our platform is based on the delivery of these high cost, specialty pharmaceuticals that have specialized handling and administration requirements.”

For prospective investors, MITD’s strong financial results in recent quarters, as well as the increasing demand for its value-based services, could provide the company with a platform to deliver strong returns moving forward. Look for MITD to continue building on its established position within the ambulatory care market in order to capitalize on rising demand in the years to come.

For more information on MIT Holding, visit www.mitholdinginc.com

Let us hear your thoughts: MIT Holding, Inc. Message Board

ENGlobal recenlty announced that it is one of three companies who will be receiving a multiple-award contract by the U.S. Military for the procurement of automated fuel handling equipment (AFHE) support services. Estimated value of the fixed-price contracts is approximately $215 million. Also, there are prospects that the work could continue to June 2017 if the contract reaches the $215 million figure. Contract factors are contingent upon the U.S. Navy exercising all options.

ENG’s role in the project consists of development, engineering, design, integration, fabrication, logistics, installation, quality assurance, logistics, life-cycle management, maintenance, and technical support for AFHE systems. The primary focus for the company will be on an indefinite-delivery/indefinite-quantity (ID/IQ), cost-plus-fixed-fee contract for technical and maintenance services for automated tank gauging and automated fuel service stations. Work will be performed at the DOD fuel facilities worldwide. Completion date is expected to be by the second quarter 2013.

Edward L. Pagano, ENGlobal’s President and Chief Executive Officer commented, “ENGlobal has a proven track record of delivering exceptional service to SPAWAR since 2007.” “This cumulative award for the three firms represents an increase of approximately $89 million over the 2007 award level of $126 million and, as validated by our performance, we will make every effort to increase ENGlobal’s portion of the base contract funding.”

Mr. Pagano further added, “Our Government Services division, based in Tulsa, Oklahoma, specializes in the turn-key installation and maintenance of automation and instrumentation systems for the U.S. defense industry worldwide. This award demonstrates that our technical capability for AFHE engineering support extends globally to keep Department of Defense fuel systems fully mission capable.”

Further information about the company and its businesses is available at www.ENGlobal.com

In 1996, California became the first state in the country to legalize the use of medical cannabis when it enacted Proposition 215. Less than two decades later, a total of 23 states, as well as the District of Columbia, have legalized marijuana for medicinal purposes, and that progress has come without a single clinical trial taking place. To this point, the medicinal cannabis market has existed without facing many of the regulatory hurdles present in the pharmaceutical industry, but that could be changing soon. With the movement to reclassify cannabis as a schedule II drug at the federal level rapidly gaining steam, the current landscape of the medical cannabis industry could be closing in on a period of transformation.

As a schedule II drug, cannabis could be recognized as a therapeutic treatment with an accepted medical use in the United States, which would dramatically increase the marketability of cannabis-based pharmaceuticals. This shift in perception would likely entice major pharmaceutical players to begin studying the medicinal benefits of marijuana. GrowBLOX Sciences, Inc. (OTCQB: GBLX), through the development and commercialization of its proprietary GrowBLOX technology suite, is prepared to capitalize on this market evolution by providing an unrivalled approach to consistent cannabis production.

The GrowBLOX technology suite was specially engineered to safely and reliably deliver consistent cannabis products by preserving and replicating carefully chosen genetic stock and precisely controlling the growing process. By monitoring everything from lighting conditions and temperature to oxygen and carbon dioxide levels, the company’s innovative products allow for the elimination of many limiting variables in order to maximize the accuracy and consistency of both clinical testing and full-scale production efforts.

In an interview with TNMNews, César Cordero Krüger, chief executive officer of GB Sciences Puerto Rico, provided investors with a detailed look at the vast market potential for GrowBLOX’s groundbreaking cultivation suite as the medical cannabis industry continues to mature. According to Krüger, the epicenter of future medical marijuana production isn’t located in the continental United States, but in the U.S. territory of Puerto Rico.

Puerto Rico’s history as a medical marijuana hub is just beginning. In 2014, Governor Alejandro Garcia Padilla signed an executive order authorizing the manufacturing of medical marijuana across the island. Although details are still under wraps, Krüger highlighted the possibility that the government’s future plans could involve the University of Puerto Rico, giving the local industry access to the university’s molecular science building, cancer research facilities and independent laboratory testing.

With one of the densest concentrations of pharmaceutical industries in the world, Puerto Rico appears to have a major role to play in the future of the medical cannabis industry. Likewise, look for GrowBLOX and its subsidiaries to make waves with the continued development and commercialization of the GrowBLOX technology suite.

For more information, visit www.growblox.com

To listen to the full conversation with César Cordero Krüger, visit www.tnmnews.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

Fastfunds Financial Corp. operates through two wholly owned subsidiaries, Cannabis Angel, Inc. and The 420 Development Corporation, to build a portfolio of revenue-generating companies that provide ancillary services to the burgeoning cannabis industry. The company also operates majority-owned subsidiary Financiera Moderna, Inc., which offers financial services to the underserved Hispanic community. FFFC’s strategy to participate in the marijuana industry is through the development of four separate business verticals for the emerging U.S. cannabis industry.

Through its 49% stake in Cannabis Merchant Financial Solutions, Inc. (CMFS), FFFC entered the Financial Service business vertical. CMFS developed the Green Card and Tommy Chong Green Card, a reloadable stored value card with a rewards feature, and the Tommy Chong Frequent Buyers Card, which functions as a gift card or rewards card. FFFC is developing a national group of master resellers, distributors and sales representatives for these card products.

As the cannabis industry continues to develop, FFFC is partaking in Plant Botany, specifically the development of methods and technologies to significantly enhance plant growth and purity. Under an operating agreement with Sanidor Systems to create Pure Grow Systems, LLC, FFFC acquired a 49% interest in the subsidiary, which is dedicated to the healthy production and processing of raw materials used for medicinal or other health related purposes.

The cannabis industry is a cash-only business, which leaves companies vulnerable to criminal activities. FFFC plans to address this issue and enter the Security Services and Equipment sector through the acquisition of an existing, operational security company. FFFC owns a 70% stake in Ohio-based Brawnstone Security, Inc., a diversified security, training and investigations company. FFFC’s research shows that operating margins for cannabis-related security services could exceed current billing levels by at least 100%.

FFFC’s Cannabis Angel, Inc. (“CA”) subsidiary will evaluate and provide corporate development services and early seed financing for worthwhile development-stage cannabis ventures. To date, CA has made investments in companies involved in the distribution of cannabis-related products and development of a social media website. It is important to note that all of FFFCs activities in the cannabis industry are ancillary, or pick and shovel, and are evaluated to insure compliance with all state and federal Laws.

For more information, visit www.fastfundsfinancial.com

Let us hear your thoughts: Fastfunds Financial Corp. Message Board

LightPath Technologies, Inc. (NASDAQ: LPTH) is a recognized leader in optics and photonics solutions, serving blue chip customers in the industrial, defense, telecommunications, testing and measurement, and medical industries for over a quarter of a century. The company designs, manufactures and distributes a full range of optical and infrared (IR) components for direct sale to customers throughout North America and China, as well as through distributors and channel partners in Europe and the United States. LightPath’s current product offerings include molded glass aspheric lenses and assemblies, IR lenses and thermal imaging assemblies, fused fiber collimators and gradient index GRADIUM® lenses.

In recent weeks, LightPath has taken strides toward expanding its market share through the continued development and commercialization of its innovative IR product line. The potential applications for the company’s IR technology are plentiful – including small hand-held cameras for thermography, maintenance and security applications, in-process quality assurance monitoring, and medical sensing devices. In June, LightPath highlighted one pivotal application when it partnered with a leading supplier of integrated products and technologies to supply its proprietary IR molded optics for use in the manufacture of firefighting thermal imaging cameras. In total, the company’s IR products currently account for more than 10 percent of its consolidated annualized revenues.

“We are extremely excited by the growth in market opportunities of our infrared product line,” Jim Gaynor, president and chief executive offer of LightPath, stated in a news release. “The launch of our proprietary infrared product technologies positions us to participate in an estimated $3.5 billion global market… that will contribute to revenue growth for LightPath.”

During its fiscal quarter ending March 31, 2015, LightPath provided prospective investors with a preview of its massive market potential by posting strong financial results. In addition to recording a 193 percent year-over-year increase in revenue from the sales of IR products, the company realized a six percent year-over-year rise in overall revenue. These results helped LightPath record a net income for the period of approximately $90,000.

“We had an excellent fiscal 2015 third quarter that reflects the actions taken in the first half of the year to accelerate sales and improve our operating efficiency,” continued Gaynor. “We are benefitting from growth in both our precision molded optic product line and infrared product line and operational efficiencies to drive improved profitability.”

With growing demand for its IR product line leading the way, LightPath is in a strong strategic position to build upon its industry presence moving forward. For potential investors, the company’s recent financial growth could foreshadow an opportunity to capitalize on sustainable returns in the years to come.

For more information, visit www.lightpath.com

On the Move Systems, exploring new online tools to reduce costs and increase convenience in the tourism and travel industry and exploring new opportunities in trucking, today pointed to a recent industry survey as validation of the company’s revolutionary shared economy business model.

A respected industry survey revealed truckers are actively looking for ways to increase route optimization, which is a major selling point of OMVS’s upcoming “Uber-for-Trucking” platform.

According to GE Capital’s recently released “Trucking Industry Economic Outlook Survey,” national and local carriers are finding fewer idle trucks available for capacity; as a result, “companies have gotten smarter about the contracts and the routes that they take, and how they match those with the businesses available.”

OMVS CEO Robert Wilson explained how this finding complements OMVS’s shared economy business model now under development.

“The GE Capital survey shows truckers are putting more time and effort into selecting routes in order to optimize their business and profits,” Wilson said in the news release. “And our own market research matches the survey’s results. Both show there is a great need in the industry for our shared economy model and when it is released, we’re optimistic our revenues will throttle up quickly as truckers discover how this unique platform will positively impact their business.”

The GE Capital survey also revealed other encouraging industry signs that support OMVS’s shared economy model. Nearly half of all respondents believed the trucking business will expand in the next 12 months while more than 25 percent expect to increase their capital spending in the next year; and just under 50 percent planned to add new equipment.

These findings are highly encouraging to OMVS, which continues to recruit trucking partners for its online platform as analysts predict sales in the shared economy forecast to reach $335 billion by 2025.

For more information, visit www.onthemovesystems.com

Let us hear your thoughts: On the Move Systems Corp. Message Board

Bioheart, Inc. (OTCQB: BHRT) is an emerging enterprise in the regenerative medicine industry focused on the discovery, development and commercialization of cell-based therapeutics that prevent, treat or cure cardiovascular diseases. The company’s leading product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function in patients with severe heart damage due to a heart attack. In January, Bioheart announced plans to initiate phase III clinical studies of the candidate for the treatment of chronic heart failure in the coming months. Currently, Bioheart is aiming to achieve market approval for MyoCell in 2019.

According to the American Heart Association, approximately 4.9 million Americans are currently living with congestive heart failure, demonstrating the immense market potential for Bioheart’s primary product candidate moving forward. Using muscle stem cells known as myoblasts, MyoCell therapy addresses cardiovascular damage by promoting increased muscle formation in patients’ hearts. In clinical studies, these unique cells have survived in the low-oxygen environment of chronically damaged, scarred heart tissue better than any other cell type, and they can be genetically modified to attract the stem cells of patients in order to assist with the regenerative process.

In addition to the development of cell-based therapeutics, Bioheart promotes revenue through physician and patient-based regenerative medicine training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals and the operation of a cell therapy clinic. In the first quarter of 2015, the company leveraged these products and services to realize an increase in year-over-year revenues of nearly 25 percent, recording $490,000 for the period. In the future, Bioheart’s management team expects these revenue-generating operations to provide necessary funding to support the company’s clinical development activities, as well as general business expenses.

“We continue to advance on our plan and pathway to profitability,” Mike Tomas, president and chief executive officer of Bioheart, stated in a news release. “We remain confident in our abilities and steadfast on our objectives and desire to create positive outcomes for our patients and positive investment outcomes for our shareholders.”

For prospective shareholders, Bioheart represents an intriguing investment opportunity. The company’s unique combination of promising therapeutic candidates and revenue-generating capabilities could provide it with a platform upon which to realize sustainable growth in market share and improved financial results in the years to come.

For more information, visit www.bioheartinc.com

SofTech, Inc. (OTCQB: SOFT) enhances customer productivity and promotes profitability through the development, marketing and distribution of computer software solutions for the product lifecycle management (PLM) industry. In particular, the company’s proprietary ProductCenter® PLM solution enables users to automate product data and lifecycle processes, allowing for streamlined management of product development from concept to commercialization and beyond. Currently, over 100,000 users benefit from SofTech’s innovative portfolio of software solutions and services, including employees of General Electric Company (GE), Goodrich, Honeywell (HON), AgustaWestland and the U.S. Army.

In recent months, SofTech has leveraged the marketability of its PLM solutions to record strong financial results. Despite a year-over-year decrease in total revenues following the sale of its CADRA product line, the company recorded a 20.5 percent year-over-year increase in ProductCenter revenue in the fiscal quarter ending February 28, 2015, as two of the company’s existing customers significantly escalated their usage of the product. Moving forward, SofTech will look to build on this progress by expanding its industry reach.

“The sale of the CADRA product line in 2014 provided the capital and the flexibility for us to make a significant current year investment in the development of a new PLM-based product aimed at the consumer market,” Joe Mullaney, chief executive officer of SofTech, stated in a news release. “We believe this product has the potential to get SofTech on a revenue growth path, an essential element of shareholder value enhancement.”

Through the continued expansion of its portfolio, SofTech could be in a strong position to capitalize on the growth of the PLM industry in the years to come. According to a report by Transparency Market Research, the global PLM market is expected to grow at a compound annual growth rate of 8.1 percent from 2015 to 2022, reaching a market value of more than $75.8 billion by the end of the period. Rising demand for product innovation and enhanced productivity are expected to dramatically increase the deployment of PLM solutions in non-traditional end-use sectors, including consumer products and retail.

With over 45 years of industry experience, SofTech is an established player in the expanding PLM industry. Look for the company to leverage this positioning in order to promote continued adoption of its ProductCenter solution and prepare for the commercial launch of its groundbreaking consumer market-centric product in the coming weeks.

For more information, visit www.softech.com

When oil is produced, associated gas is also produced from the reservoir together with the oil. A large amount of this gas is used due to the fact governments and oil companies have made sizeable investments to capture it. As a result, some of it is flared because of technical, regulatory, or economic constraints. Subsequently, thousands of gas flares at oil production sites worldwide burn in the range of 140 billion cubic meters of natural gas per year resulting in more than 300 million tons of CO2 getting pushed into a once pristine atmosphere.

Gas flaring is an adverse component in climate change and impacts the environment through emission of black carbon, CO2 and a myriad of other pollutants. It also wastes a valuable energy resource that could be used to advance the sustainable development of producing countries. For example, if this amount of gas were used for power generation, it could provide about 750 billion kWh of electricity, which amounts to more than the African continent’s current annual electricity consumption.

Well Power (OTCQB: WPWR) is focused on ways it can help curb gas flaring, a gnawing and growing problem in the United States. As evidence of its endeavors, the company has acquired an exclusive license to distribute ME Resources’ micro refinery unit (MRU) and has been persistent in promoting this flare-reducing technology to interested investors.

The company is active in adding talented, human capital its operations. Earlier this year, WPWR increased the seats on its board of directors to include Robert V. Shields. Mr. Shields’ impressive skill set is derived from entrepreneurship, professional engineering of more than three decades as well as tenure within the petroleum industry veteran. Specifically, Mr. Shields’ petroleum industry experience comes from the economic evaluations, drilling, production operations, and identifying and securing international exploration mineral leases.

Well Power is a development stage company that focuses on distributing micro-refinery units in Texas and internationally. The company intends to provide oil and gas producers solutions to process wasted natural gas, including stranded, shut-in, flared, and vented gas; and produce engineered fuel and electrical power.

For more information on the company, visit www.wellpowerinc.com

Let us hear your thoughts: Well Power Inc. Message Board

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) is a biopharmaceutical company focused on the development of targeted antiviral therapies. The company’s leading product candidate, FV-100, is currently in phase III clinical development for the treatment of shingles, as well as for the prevention of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). Additionally, ContraVir’s product pipeline includes CMX157, which is scheduled to be evaluated in a phase II clinical study for the treatment of hepatitis B virus in the coming months.

While there are already antivirals approved to treat the viral infection underlying shingles, there are currently no approved antiviral therapies for the prevention of PGN. According to a report by the National Institute of Health, an estimated one million Americans suffer from shingles each year, and more than 65 percent of those individuals suffer from PHN for 30 days or more. In some cases, PHN symptoms can persist for well over two years if left untreated. Through the eventual commercialization of FV-100, ContraVir will gain access to this critically underserved market segment within the biopharmaceutical industry. In clinical trials, FV-100 demonstrated a clinically meaningful 37 percent reduction in the incidence of PHN versus the current standard of care.

In addition to FV-100, the company continues to make clinical progress with CMX157. In June, ContraVir took a major step in the development of CMX157 by partnering with the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments with the company’s drug candidate. Specifically, these tests will focus on comparing the relative anti-hepatitis B activities of CMX157 with those of tenofovir, the current standard of care, in order to determine if the candidate has unique attributes not previously appreciated of other antiviral agents.

“The Blumberg Institute’s commitment to advancing new therapies for hepatitis B make them an ideal research and development vehicle for ContraVir,” James Sapirstein, chief executive officer of ContraVir, stated in a news release. “This association will help advance our CMX157 candidate and may further de-risk the development process going forward, as we prepare to enter phase II clinical studies.”

For prospective shareholders, ContraVir’s considerable developmental progress could foreshadow an opportunity to realize sustainable returns moving forward. Following its uplisting to the NASDAQ Capital Market earlier this year, the company is in a strong strategic position to capitalize on improved visibility in the coming months. Look for ContraVir to leverage the opportunities presented by this visibility in order to optimize market growth as it continues toward the commercialization of its advanced product pipeline.

For more information, visit www.contravir.com